Figures
- Fig. 1.—
Baseline St Georges Respiratory Questionnaire (SGRQ) scores by exacerbation category. Data are presented as mean and 95% confidence intervals (bars). Baseline SGRQ score was missing for six infrequent exacerbators and for five frequent exacerbators. High score indicates worse health. #: p=0.002; ¶: p=0.03. None, n=91; infrequent, n=279; frequent, n=230.
- Fig. 2.—
Deterioration in St Georges Respiratory Questionnaire (SGRQ) total score by exacerbation category. Data are presented as mean and 95% confidence intervals (bars). Higher score indicates faster deterioration in health. #: p<0.0001; ¶: p=0.004. None, n=91; infrequent, n=285; frequent, n=235.
Tables
- Table 1—
Baseline characteristics by exacerbation status: exacerbators versus nonexacerbators
Number of exacerbations Frequency of exacerbations None ≥1 p-value <1.65·yr−1 >1.65·yr−1 p-value Subjects n 93 520 291 286 Sex M % 86 73 0.009 72 74 0.7 Age yrs 65±7 64±7 0.06 63±7 64±7 0.05 Current smokers % 52 48 0.6 48 48 0.9 SGRQ total score 42±17 50±17 <0.0001 48±18 52±15 0.03 FEV1 % pred 55±15 49±15 0.001 53±15 45±13 <0.0001 -
Data are presented as mean±sd unless otherwise stated
-
Mean exacerbation rate in patients with exacerbations >0 and <1.65·yr−1 was 0.9·yr−1, and in patients with exacerbations >1.65·yr−1 was 2.8·yr−1
-
M: male
-
SGRQ: St Georges Respiratory Questionnaire
-
FEV1: forced expiratory volume in one second
-
- Table 2—
Effect of treatment and exacerbation frequency on change in St Georges Respiratory Questionnaire (SGRQ) score
SGRQ score units·yr−1 p-value Exacerbation frequency None 2.0 0.0003 Infrequent 2.4 Frequent 2.9 Treatment FP 2.2 0.02 Placebo 2.6 -
Data are presented as mean or as p-value
-
FP: fluticasone proprionate
-
- Table 3—
Relationship between deterioration in St Georges Respiratory Questionnaire (SGRQ) score, exacerbation group and treatment
SGRQ score units·yr−1 p-value Exacerbation group None 2.0 0.0003 Infrequent 2.4 Frequent 2.9 Treatment FP 2.3 0.1 Placebo 2.5 Exacerbation group * treatment 0.2 -
Data are presented as mean or p-value
-
FP: fluticasone proprionate
-
- Table 4—
Relationship between deterioration in St Georges Respiratory Questionnaire (SGRQ) score, forced expiratory volume in one second (FEV1) decline and treatment
FEV1 decline mL·yr−1·1 unit SGRQ−1 SGRQ score mean units·yr−1 p-value FEV1 decline rate −6.3 <0.0001 Treatment FP 2.3 0.02 Placebo 2.7 FEV1 decline * treatment 0.2 -
FP: fluticasone proprionate
-
